SG11202011502VA - Methods of treating patients at risk for renal injury and renal failure - Google Patents
Methods of treating patients at risk for renal injury and renal failureInfo
- Publication number
- SG11202011502VA SG11202011502VA SG11202011502VA SG11202011502VA SG11202011502VA SG 11202011502V A SG11202011502V A SG 11202011502VA SG 11202011502V A SG11202011502V A SG 11202011502VA SG 11202011502V A SG11202011502V A SG 11202011502VA SG 11202011502V A SG11202011502V A SG 11202011502VA
- Authority
- SG
- Singapore
- Prior art keywords
- renal
- risk
- methods
- treating patients
- injury
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862676157P | 2018-05-24 | 2018-05-24 | |
US201862715508P | 2018-08-07 | 2018-08-07 | |
PCT/US2019/034018 WO2019227055A1 (en) | 2018-05-24 | 2019-05-24 | Methods of treating patients at risk for renal injury and renal failure |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011502VA true SG11202011502VA (en) | 2020-12-30 |
Family
ID=66867810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202011502VA SG11202011502VA (en) | 2018-05-24 | 2019-05-24 | Methods of treating patients at risk for renal injury and renal failure |
Country Status (13)
Country | Link |
---|---|
US (1) | US11435364B2 (en) |
EP (1) | EP3803409A1 (en) |
JP (1) | JP2021526221A (en) |
KR (1) | KR20210019459A (en) |
CN (1) | CN112384807A (en) |
AU (1) | AU2019272960A1 (en) |
BR (1) | BR112020023943A2 (en) |
CA (1) | CA3101470A1 (en) |
IL (1) | IL278925A (en) |
MX (1) | MX2020012637A (en) |
SG (1) | SG11202011502VA (en) |
WO (1) | WO2019227055A1 (en) |
ZA (1) | ZA202007317B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4125860A4 (en) * | 2020-03-23 | 2024-04-03 | Renibus Therapeutics Inc | Stress test and treatment of chronic kidney disease |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090053182A1 (en) * | 2007-05-25 | 2009-02-26 | Medistem Laboratories, Inc. | Endometrial stem cells and methods of making and using same |
JP4923146B2 (en) | 2008-01-11 | 2012-04-25 | リアタ ファーマシューティカルズ インコーポレイテッド | Synthetic triterpenoids and methods of use in the treatment of disease |
EP2324354B1 (en) | 2008-08-29 | 2014-07-16 | Astute Medical, Inc. | Methods for prognosis of acute renal failure |
CN104391116B (en) | 2008-10-21 | 2016-09-07 | 阿斯图特医药公司 | Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure |
CN104330574B (en) | 2008-11-10 | 2017-04-12 | 阿斯图特医药公司 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
JP5827226B2 (en) | 2009-08-07 | 2015-12-02 | アスチュート メディカル,インコーポレイテッド | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
JP5775874B2 (en) * | 2009-08-28 | 2015-09-09 | アスチュート メディカル,インコーポレイテッド | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
EP3070474A3 (en) | 2010-02-26 | 2016-12-07 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
ES2721907T3 (en) | 2011-08-26 | 2019-08-06 | Astute Medical Inc | Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency |
EP2841945A4 (en) | 2012-04-24 | 2016-04-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury |
ES2861393T3 (en) * | 2012-04-27 | 2021-10-06 | Reata Pharmaceuticals Inc | 2,2-Difluoropropionamide derivatives of methyl bardoxolone, pharmaceutical compositions and polymorphs thereof for use in the treatment of certain conditions |
CN105074466B (en) * | 2013-01-17 | 2018-01-09 | 阿斯图特医药公司 | methods and compositions for diagnosis and prognosis of renal injury and renal failure |
KR20160039682A (en) | 2013-08-07 | 2016-04-11 | 아스튜트 메디컬 인코포레이티드 | Assays for timp2 having improved performance in biological samples |
GB201317286D0 (en) * | 2013-09-30 | 2013-11-13 | Calscience Internat Ltd | Composition and Use |
MX2016005834A (en) | 2013-11-06 | 2016-11-17 | Astute Medical Inc | Assays for igfbp7 having improved performance in biological samples. |
EP3099380B1 (en) * | 2014-01-28 | 2021-08-11 | Buck Institute for Research on Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
US9375408B2 (en) * | 2014-09-02 | 2016-06-28 | Bhupinder Singh | Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment |
EP3200582B1 (en) * | 2014-09-29 | 2023-11-15 | Fred Hutchinson Cancer Center | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers |
-
2019
- 2019-05-24 WO PCT/US2019/034018 patent/WO2019227055A1/en unknown
- 2019-05-24 KR KR1020207037307A patent/KR20210019459A/en not_active Application Discontinuation
- 2019-05-24 SG SG11202011502VA patent/SG11202011502VA/en unknown
- 2019-05-24 EP EP19731048.5A patent/EP3803409A1/en active Pending
- 2019-05-24 AU AU2019272960A patent/AU2019272960A1/en active Pending
- 2019-05-24 US US16/422,156 patent/US11435364B2/en active Active
- 2019-05-24 MX MX2020012637A patent/MX2020012637A/en unknown
- 2019-05-24 CA CA3101470A patent/CA3101470A1/en active Pending
- 2019-05-24 CN CN201980040812.XA patent/CN112384807A/en active Pending
- 2019-05-24 JP JP2021516548A patent/JP2021526221A/en active Pending
- 2019-05-24 BR BR112020023943-7A patent/BR112020023943A2/en unknown
-
2020
- 2020-11-23 IL IL278925A patent/IL278925A/en unknown
- 2020-11-24 ZA ZA2020/07317A patent/ZA202007317B/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL278925A (en) | 2021-01-31 |
KR20210019459A (en) | 2021-02-22 |
ZA202007317B (en) | 2022-08-31 |
MX2020012637A (en) | 2021-04-28 |
WO2019227055A1 (en) | 2019-11-28 |
US11435364B2 (en) | 2022-09-06 |
US20230314448A1 (en) | 2023-10-05 |
CA3101470A1 (en) | 2019-11-28 |
US20200057076A1 (en) | 2020-02-20 |
AU2019272960A1 (en) | 2020-12-10 |
JP2021526221A (en) | 2021-09-30 |
EP3803409A1 (en) | 2021-04-14 |
CN112384807A (en) | 2021-02-19 |
BR112020023943A2 (en) | 2021-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276398A (en) | Combination therapy for the treatment of mastocytosis | |
IL270956A (en) | Methods of treating fabry patients having renal impairment | |
HK1257321A1 (en) | Histotripsy therapy systems and methods for the treatment of brain tissue | |
IL276301A (en) | System and method for patient engagement | |
PL3253443T3 (en) | Apparatus for treatment of snoring and sleep apnoea | |
IL256256A (en) | System and method for extracorporeal blood treatment | |
IL282871A (en) | Systems and methods for skin treatment | |
IL274019A (en) | System and method for prediction of medical treatment effect | |
IL288677A (en) | Methods of treating fabry disease in patients having renal impairment | |
IL269083A (en) | Methods for preventing and treating heart disease | |
HK1257240A1 (en) | Medicine for preventing and treating tissue injury caused by abnormal fat deposition and use of the medicine | |
GB2583322B (en) | Method for managing behavioral treatment therapy and devices thereof | |
IL282643A (en) | Combination therapy for treatment of hematological diseases | |
EP3556388A4 (en) | Method for preventing and treating pathological renal tissue injury | |
GB201519557D0 (en) | Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions | |
IL290770A (en) | Compounds and methods for treating oxalate-related diseases | |
PL3731893T3 (en) | Apparatus for extracorporeal blood treatment | |
IL284462A (en) | Systems and methods for tissue treatment | |
ZA202007317B (en) | Methods of treating patients at risk for renal injury and renal failure | |
IL276639A (en) | Agents and methods for treating dysproliferative diseases | |
GB201706747D0 (en) | Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients | |
GB202005231D0 (en) | Method of mimimising patient risk | |
HK1257238A1 (en) | Medicine for preventing and treating lipid kidney injury and use of the medicine | |
PL3431119T3 (en) | Apparatus for extracorporeal treatment of blood | |
IL292186A (en) | Compositions and methods for treating blood disorders |